ALK TKI
Approval in the
crizotinib-failure setting
Ongoing studies in
ALK inhibitor-naïve
setting
Ceritinib
FDA approved (April 2014)
EU approved (May 2015)
Phase III
(vs chemo)
Press release: positive
study
Alectinib
Approved in Japan (April
2014)
FDA approved (December
2015)
Phase III
(vs crizotinib)
Brigatinib
Investigational
FDA breakthrough therapy
Phase III
(vs crizotinib)
Ensartinib
Investigational
Phase III
(vs crizotinib)
Phase III
Next generation ALK inhibitors in crizotinib resistance
Novello, et al. Ann Oncol 2016
Recommended in t 2016
ESMO guidelines
